ArticleResearch and practice in thrombosis and haemostasis2025
Plasma microRNA-145-5p as a diagnostic biomarker for acute deep vein thrombosis.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Circulating MicroRNAs as Biomarkers and Therapeutic Targets in Venous Thromboembolism: A Systematic Review.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Identification of new biomarkers for acute deep vein thrombosis (DVT) that could lower the need for diagnostic imaging to confirm or rule out the diagnosis would be advantageous. microRNA-145-5p (miR-145) has the potential to be a diagnostic marker for acute DVT, but its diagnostic performance has not been evaluated in consecutive patients referred to the hospital with suspected DVT. Objectives: The aim of this study was to assess the diagnostic performance of miR-145 for the diagnosis of acute lower extremity DVT. Methods: Patients consecutively referred to the emergency room at Akershus University Hospital (Norway) due to suspicion of acute DVT between June 2021 and July 2023 were included. Within 24 hours of admission, blood was collected for assessment of plasma miR-145 (index test), and whole-leg compression ultrasound (reference standard) was used to confirm or rule out DVT. Cohen's d effect size and area under the receiver operating curve (AUC) were used to estimate the diagnostic performance of miR-145 and D-dimer. Results: Among 360 included patients, 101 (28%) were diagnosed with DVT. miR-145 showed poor diagnostic performance, as indicated by a Cohen's d of -0.002 (95% CI, -0.241 to 0.216) and an AUC of 0.59 (95% CI, 0.51-0.67). For D-dimer, Cohen's d was 1.66 (95% CI, 1.43-1.89), and the AUC was 0.92 (95% CI, 0.86-0.96). Conclusion: Plasma levels of miR-145 showed poor diagnostic performance for lower extremity acute DVT among persons referred to the emergency room with clinical signs and symptoms of DVT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.